Phase 3
Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib as a treatment for moderate to severe atopic dermatitis in adult patients.
The findings showed that a clinically significant proportion of the trial’s participants taking either 1mg and 2mg doses of baricitinib achieved a change of at least 75% according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment, meeting the primary endpoint of the study.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
